Future Science Group

Taylor & Francis Group
  • 5,0 (2)
  • Наука
  • Дважды в месяц

Podcast by Taylor & Francis Group

  1. 17 июн.

    Enzalutamide in biochemically recurrent prostate cancer: key findings from the EMBARK study

    This podcast features two of the investigators from the international, randomized, Phase III EMBARK trial (NCT02319837) in conversation. EMBARK evaluated the efficacy and safety of enzalutamide plus androgen deprivation therapy and enzalutamide monotherapy, as compared with androgen deprivation therapy alone, in patients with nonmetastatic castration-sensitive prostate cancer and biochemical recurrence at high risk for metastasis. In this podcast, the second in the EMBARK series, the speakers discuss the key efficacy and safety findings from the trial, consider some of the patient-reported outcomes and their implications for quality of life, and review some of the implications for clinical practice.

    26 мин.
  2. Practical advice on implementing DESTINY-Breast09 trial data into clinical practice

    11 июн.

    Practical advice on implementing DESTINY-Breast09 trial data into clinical practice

    In this interview, discover discuss key findings from the DESTINY-Breast09 trial and their implications for clinical practice, including practical advice for oncologists exploring treatment sequencing strategies with T-DXd.

    7 мин.
  3. 2026 BRSA Finalist Giorgi Kobidze

    18 мая

    2026 BRSA Finalist Giorgi Kobidze

    Meet Giorgi Kobidze, your 2026 BRSA finalist.

    1 мин.
  4. 2026 BRSA Finalist Richa Pandey

    18 мая

    2026 BRSA Finalist Richa Pandey

    Meet Richa Pandey, your 2026 BRSA finalist.

    29 сек.
  5. Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study

    18 мая

    Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study

    Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study by Taylor & Francis Group

    20 мин.
  6. 2026 BRSA Finalist Dakshat Trivedi

    18 мая

    2026 BRSA Finalist Dakshat Trivedi

    Meet Dakshat Trivedi, your 2026 BRSA finalist.

    1 мин.
  7. 2026 BRSA Finalist Ethan Sanford

    18 мая

    2026 BRSA Finalist Ethan Sanford

    Meet Ethan Sanford, your 2026 BRSA finalist.

    28 сек.
  8. Harmonizing scientific innovation, patient care and regulation in advanced therapies: a podcast with Patrice Faloye

    27 апр.

    Harmonizing scientific innovation, patient care and regulation in advanced therapies: a podcast with Patrice Faloye

    Harmonizing scientific innovation, patient care and regulation in advanced therapies: a podcast with Patrice Faloye by Taylor & Francis Group

    22 мин.
См. все (316)

Оценки и отзывы

5
из 5
Оценок: 2

Об этом подкасте

Podcast by Taylor & Francis Group

Информация

  • Автор
    Taylor & Francis Group
  • Годы выхода
    2016 - 2026
  • Выпуски
    316
  • Ограничения
    Без ненормативной лексики
  • Авторские права
    © All rights reserved
  • Сайт подкаста
    Future Science Group